BBR 3611
Latest Information Update: 09 Sep 2003
At a glance
- Originator Novuspharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 09 Sep 2003 Discontinued - Preclinical for Cancer in Italy (unspecified route)
- 24 Oct 2001 Preclinical development for Cancer in Italy (Unknown route)